Myriad Genetics Stock Plunges After Supreme Court Loss
Image by courtesy of lisa schlager
The stock of Myriad Genetics plunged after the Supreme Court rejected its effort to patent a human gene mutation that is linked to cancer and is common among Ashkenazi Jews.
Shares of the biotech company dropped about 15% on Friday after spiraling up by about 10% on Thursday.
The stock initially rocketed up by more than 10% in the hours after the Supreme Court decision was announced. Initial reports put a positive spin on the decision’s potential effects on the company’s lucrative effort to corner the market on the BRCA-1 gene mutation that leads to a higher risk of breast cancer.
But as more information emerged about the unanimous ruling, it gave back the gains and turned sharply negative.
Analysts say other companies may now enter the market for testing for the mutation, which may lower the price of the tests and sharply reduce Myriad’s profits.
The company’s stock had soared last month when Hollywood superstar Angelina Jolie announced she underwent a double mastectomy to avoid the risk of breast cancer related to the BRCA1 defect.
At that time, analysts pointed out that Jolie’s star power would likely spur more women to undergo the tests, which would in turn boost Myriad’s revenue.
A message from our Publisher & CEO Rachel Fishman Feddersen
I hope you appreciated this article. Before you go, I’d like to ask you to please support the Forward’s award-winning, nonprofit journalism during this critical time.
We’ve set a goal to raise $260,000 by December 31. That’s an ambitious goal, but one that will give us the resources we need to invest in the high quality news, opinion, analysis and cultural coverage that isn’t available anywhere else.
If you feel inspired to make an impact, now is the time to give something back. Join us as a member at your most generous level.
— Rachel Fishman Feddersen, Publisher and CEO
